Ocular Therapeutix (OCUL) grants RSUs, options to chief medical officer

Rhea-AI Filing Summary

Ocular Therapeutix Chief Medical Officer Nadia Waheed reported new equity awards. On January 2, 2026, she received 79,112 restricted stock units (RSUs), each representing one share of common stock, at a grant price of $0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in two equal annual installments, subject to her continued service.

On the same date, she was also granted a stock option for 240,932 shares of common stock at an exercise price of $11.82 per share. This option vests over four years, with 1/48 of the underlying shares vesting monthly beginning one month after the grant date, conditioned on continued service. Following the RSU grant, she beneficially owned 326,280 shares of common stock directly, along with the newly granted option covering 240,932 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Waheed Nadia

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	240,932	$0.00	--
Grant/Award	Common Stock	79,112	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 240,932 shares (Direct); Common Stock — 326,280 shares (Direct)

Footnotes (1)

1. On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waheed Nadia

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		79,112(1)	A	$0	326,280	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.82	01/02/2026		A		240,932		(2)	01/01/2036	Common Stock	240,932	$0	240,932	D

Explanation of Responses:

1. On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

2. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

Remarks:

Exhibit Index. Exhibit 24 - Power of Attorney

	/s/ Todd Anderman, Attorney-in-Fact for Nadia Waheed	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OCUL report for Nadia Waheed?

The filing reports equity awards to Chief Medical Officer Nadia Waheed, including a grant of restricted stock units and a stock option, rather than a sale of existing shares.

How many RSUs were granted to the Ocular Therapeutix (OCUL) CMO?

Nadia Waheed received 79,112 restricted stock units (RSUs), each representing the right to receive one share of Ocular Therapeutix common stock, subject to time-based vesting.

What are the vesting terms for the new OCUL RSUs?

The 79,112 RSUs vest over three years: one-third vests on the one-year anniversary of the January 2, 2026 grant date, and the remaining two-thirds vest in equal annual installments, all subject to continued service.

What stock option was granted in this Ocular Therapeutix Form 4?

Nadia Waheed was granted a stock option for 240,932 shares of common stock with an exercise price of $11.82 per share, reported as acquired at $0 on the grant date.

How does the stock option for OCUL shares vest?

The option for 240,932 shares vests over four years, with 1/48 of the shares vesting monthly beginning on the one-month anniversary of the January 2, 2026 grant date, subject to continued service.

How many OCUL common shares does Nadia Waheed hold after this grant?

After the reported transaction, Nadia Waheed beneficially owned 326,280 shares of Ocular Therapeutix common stock directly, plus the newly granted option for 240,932 shares.